Shanghai medicine - enalapril maleate tablets pass the consistency evaluation

On December 24, Shanghai Pharmaceutical released a notice that enalapril maleate tablets (5mg, 10mg) of Changzhou pharmaceutical factory, a holding subsidiary of Shanghai pharmaceutical, were awarded the approval document for supplementary application for drugs (approval No.: 2019b04546, 2019b04551) issued by the State Food and drug administration, and the drug passed the consistency evaluation of generic drugs Enalapril maleate tablets are mainly used in the treatment of primary hypertension, renal vascular hypertension, heart failure at all levels, prevention of symptomatic heart failure, prevention of coronary artery ischemia events in patients with left ventricular dysfunction They were developed by Merck and first listed in Japan in 1986 In October 2018, Changzhou pharmaceutical filed an application with the State Food and Drug Administration for the consistency evaluation of generic drugs and was accepted In 2018, Changzhou pharmaceutical's sales revenue of the drug was RMB 17.39 million As of the date of this announcement, the main manufacturers of the drug in China are Yangzijiang Pharmaceutical Group Jiangsu Pharmaceutical Co., Ltd., Shiyao group Ouyi Pharmaceutical Co., Ltd and Hunan qianjinxiangjiang Pharmaceutical Co., Ltd As of the date of this announcement, the company has invested about 8.7812 million yuan in the R & D cost for the consistency evaluation of the drug According to iqvia database, the purchase amount of the drug hospital in 2018 was RMB 199680000 Adorable adorable